Dyslipidaemia

Praluent® (alirocumab) Administration

Therapeutic indications for Praluent® (alirocumab)

Specific characteristics of Praluent® (alirocumab)

NICE and SMC Guidance Praluent® (alirocumab)

ODYSSEY OUTCOMES Safety Profile Praluent® (alirocumab)

ESC/EAS DYSLIPIDAEMIA GUIDELINE INTERACTIVE (1 HOUR)

We know your time is precious, how long do you have?

ESC/EAS DYSLIPIDAEMIA GUIDELINE INTERACTIVE (2 MINUTES)

We know your time is precious, how long do you have?

ESC/EAS DYSLIPIDAEMIA GUIDELINE INTERACTIVE (20 MINUTES)

We know your time is precious, how long do you have?

ODYSSEY OUTCOMES Efficacy Praluent® (alirocumab)

ODYSSEY OUTCOMES Trial Design Praluent® (alirocumab)

Praluent® (alirocumab) mechanism of action

Dosing options – customise your patient’s treatment with Praluent® (alirocumab)

Praluent® (alirocumab) PubExplainer

Short videos summarizing key trial data

A cardiologist's view - Professor Azfar Zaman

Cardiovascular outcomes for diabetes patients Praluent® (alirocumab)

FH I & FH II Studies Praluent® (alirocumab)

Unmet Needs in Dyslipidaemia